Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1534125 | 0.97 | DPP4 (0.50) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL38740 | 0.97 | DPP4 (0.50) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL1683556 | 0.97 | DPP4 (0.50) | DPP4F2HTR2ATAAR1ADRA2A | |
| Hydrochloric Acid SCHEMBL3919212 | 0.95 | DPP4 (0.48) | DPP4F2HTR2ATAAR1ADRA2A | |
| Water SCHEMBL5430575 | 0.95 | DPP4 (0.48) | DPP4F2HTR2ATAAR1ADRA2A | |
| Hydrochloric Acid SCHEMBL11329469 | 0.93 | DPP4 (0.46) | DPP4F2HTR2ATAAR1ADRA2A | |
| Hydrochloric Acid SCHEMBL28317319 | 0.93 | DPP4 (0.46) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL6291617 | 0.84 | ADRB2 (0.31) | DPP4F2 | |
| SCHEMBL9256933 | 0.80 | DPP4 (0.36) | DPP4F2HTR2A | |
| SCHEMBL5687743 | 0.75 | MEN1 (0.40) | HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021262825-A2 | DISRUPTING LIPID SYNTHESIS: A NOVEL TARGET FOR BROAD-SPECTRUM HOST-DIRECTED ANTI-VIRULENCE THERAPEUTICS | GENETIC NETWORKS, LLC (US) | 2021-12-30 | — | — | WO | claimed |
| US-10639308-B2 | sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2020-05-05 | — | — | US | claimed |
| US-20200087367-A1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | ACCELERON PHARMA INC. | 2020-03-19 | — | — | US | claimed |
| CN-110603049-A | Compositions and methods for treating heart failure | 阿塞勒隆制药公司 | 2019-12-20 | — | — | CN | claimed |
| EP-2953558-B1 | EMBRYO TRANSFER CATHETER | SILLENDER MARK (AU) | 2019-08-28 | — | — | EP | claimed |
| US-10154856-B2 | Therapeutic substance transfer catheter and method | SILLENDER MARK (AU) | 2018-12-18 | — | — | US | claimed |
| WO-2018144968-A1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | ACCELERON PHARMA INC. (US) | 2018-08-09 | — | — | WO | claimed |
| EP-3160464-A1 | USE OF BUSPIRONE METABOLITES | Contera Pharma APS (DK) | 2017-05-03 | — | — | EP | claimed |
| WO-2015197079-A1 | USE OF BUSPIRONE METABOLITES | CONTERA PHARMA APS (DK) | 2015-12-30 | — | — | WO | claimed |
| US-20150359566-A1 | THERAPEUTIC SUBSTANCE TRANSFER CATHETER AND METHOD | SILLENDER MARK (US) | 2015-12-17 | — | — | US | claimed |
| EP-2953678-A1 | THERAPEUTIC SUBSTANCE TRANSFER CATHETER AND METHOD | Sillender, Mark (AU) | 2015-12-16 | — | — | EP | claimed |
| EP-2953558-A1 | EMBRYO TRANSFER CATHETER AND METHOD | Sillender, Mark (AU) | 2015-12-16 | — | — | EP | claimed |
| US-20150342642-A1 | EMBRYO TRANSFER CATHETER AND METHOD | SILLENDER MARK (US) | 2015-12-03 | — | — | US | claimed |
| WO-2015051336-A1 | COMPOSITIONS AND METHODS FOR TREATING PELVIC PAIN AND OTHER CONDITIONS | WISE DAVID (US) | 2015-04-09 | — | — | WO | claimed |
| WO-2014121333-A1 | EMBRYO TRANSFER CATHETER AND METHOD | SILLENDER MARK (AU) | 2014-08-14 | — | — | WO | claimed |
| WO-2014121332-A1 | THERAPEUTIC SUBSTANCE TRANSFER CATHETER AND METHOD | SILLENDER MARK (AU) | 2014-08-14 | — | — | WO | claimed |
| US-20100034884-A1 | LUMINESCENT CONDUCTING NANO-DRUG CRYSTAL ULTRA-THIN FILM SELF-ASSEMBLY AND USES | ZHONGSHAN HOSPITAL, FUDAN UNIVERSITY (CN) | 2010-02-11 | — | — | US | claimed |
| US-7125559-B2 | Cosmetic or dermatological composition comprising a combination of an elastase inhibitor of the N-acylaminoamide family and at least one myorelaxing agent | L'OREAL (FR) | 2006-10-24 | — | — | US | claimed |
| US-20240228520-A9 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2024-07-11 | — | — | US | disclosed |
| WO-1992000729-A1 | DOSAGE FORM FOR ADMINISTERING A DRUG TO EFFECT CIRCADIAN THERAPY | ALZA CORPORATION (US) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087367-A1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | BMPR2, BMPR1B, BMP1 | DPP4 417/4885F2 1642/4885HTR2A 2718/4885 |
| US-10639308-B2 | sGC stimulators | PTGIS, CGAS, GUCY1A1 | DPP4 4670/4885F2 3090/4885HTR2A 1726/4885 |
| US-20240228520-A9 | PHOSPHORUS PRODRUGS OF PYRAZOLO-SUBSTITUTED PYRIMIDINE SGC STIMULATORS | P2RY1, P2RY11, GMPS | DPP4 2774/4885F2 2612/4885HTR2A 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.